Crohn Disease: Clinical Trials

151 trials for Crohn Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

64 completed, 23 recruiting, 23 unknown, 19 terminated. 151 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4151Completed 64, Recruiting 23, Unknown 23, Terminated 19, Withdrawn 9, Not yet recruiting 6, Active not recruiting 4, Enrolling by invitation 3

Follow Crohn Disease: new trials by email Literature Review of Crohn Disease trials Research Report on Crohn Disease

Trials (filtered) newest first · largest first

All 151 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease
Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula
Phase 4Not yet recruitingIcahn School of Medicine at Mount Sinai502026-12-012026-08-24
Emerging Indications for Hyperbaric Oxygen Treatment
Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis
Phase 4Not yet recruitingJay C. Buckey Jr.1002026-11-012026-09-09
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
Risankizumab - Crohn Disease, Perianal Fistula
Phase 4RecruitingYuki Horio252026-10-012026-10-23
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
TyboWe® Adalimumab Injection - Crohn's Disease
Phase 4RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.502026-09-232026-09-24
INSIGHT-IBD Pragmatic Study
Mirikizumab, Anti-TNF agents, anti-integrin antibodies - Ulcerative Colitis (UC), Crohn Disease (CD)
Phase 4Enrolling by invitationSpecialty Networks Research.4002026-08-122026-10-29
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative
Phase 4RecruitingJanssen Research & Development, LLC102026-08-072026-11-03
Stopping PPI Therapy in Inactive IBD
Continue PPI Therapy, Withdraw PPI Therapy - Ulcerative Colitis (UC), Crohn's Disease
Phase 4RecruitingUniversity of Nottingham802026-07-012026-07-08
Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study
Guselkumab - Crohn Disease (CD), Intensification
Phase 4RecruitingGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives2102026-06-182026-06-30
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Mirikizumab - IV, Mirikizumab - SC - Crohn Disease (CD)
Phase 4RecruitingGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives752026-05-112026-11-04
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
Mirikizumab - Crohn Disease
Phase 4RecruitingAlimentiv Inc.602026-04-202026-10-26
Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
Infliximab, Akkermansia muciniphila + Infliximab - Crohn's Diseases
Phase 4Not yet recruitingChinese Medical Association4002026-04-012026-02-17
Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
Palmitoleic Acid + Infliximab, Infliximab - Crohn's Disease
Phase 4Not yet recruitingChinese Medical Association4002026-04-012026-02-18
TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response
Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification - Crohn Disease (CD)
Phase 4RecruitingSixth Affiliated Hospital, Sun Yat-sen University3122026-03-012026-06-09
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
PK-model to decide when to dose Vedolizumab and Ustekinumab - Inflammatory Bowel Diseases, Crohn Disease
Phase 4Enrolling by invitationOdense University Hospital1662026-01-232026-11-06
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
Guselkumab (GUS) - Crohn Disease
Phase 4RecruitingXian-Janssen Pharmaceutical Ltd.782025-12-302026-11-03
Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety
Interleukin 23 - Crohn's Disease and Ulcerative Colitis
Phase 4RecruitingSixth Affiliated Hospital, Sun Yat-sen University2002025-12-012026-04-24
De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis
Ustekinumab 90 mg SC q8w, Ustekinumab 90 mg SC q12w - Crohn Disease (CD), Ulcerative Colitis (UC)
Phase 4RecruitingMcGill University Health Centre/Research Institute of the McGill University Health Centre1152025-10-082025-12-26
Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis
Mirikizumab - Crohn Disease (CD), Crohns Disease
Phase 4Not yet recruitingRubix LS1502025-07-162025-07-10
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease
Phase 4RecruitingTakeda2002025-03-272026-10-28
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
Tirzepatide, Mediterranean diet - Crohn Disease
Phase 4Active not recruitingUniversity of Miami242025-03-052026-10-29

Showing 20 of 151. Sign in to see all of them.

Narrower conditions

Colitis, Ulcerative (43)  ·  Inflammatory Bowel Diseases (36)  ·  Vitamin D Deficiency (4)  ·  Arthritis, Psoriatic (3)  ·  Arthritis, Rheumatoid (3)  ·  Bone Diseases, Metabolic (3)  ·  Intestinal Diseases (3)  ·  Iron Deficiencies (3)  ·  Anemia, Iron-Deficiency (2)  ·  Breast Feeding (2)  ·  Digestive System Diseases (2)  ·  Gastrointestinal Diseases (2)  ·  Psoriasis (2)  ·  Recurrence (2)

Broader conditions

Gastroenteritis (150)  ·  Digestive System Diseases (149)  ·  Gastrointestinal Diseases (149)  ·  Intestinal Diseases (148)  ·  Inflammatory Bowel Diseases (115)  ·  Colonic Diseases (44)  ·  Colitis (43)  ·  Nutritional and Metabolic Diseases (12)  ·  Metabolic Diseases (9)  ·  Musculoskeletal Diseases (9)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Bone Diseases (8)  ·  Pathologic Processes (6)  ·  Arthritis (5)  ·  Immune System Diseases (5)

Interventions

Infliximab (28)  ·  Adalimumab (20)  ·  vedolizumab (16)  ·  Azathioprine (9)  ·  Ustekinumab (9)  ·  Methotrexate (7)  ·  Cholecalciferol (5)  ·  Vitamin D (5)  ·  CT-P13 (4)  ·  Mercaptopurine (4)  ·  Prednisone (4)  ·  mirikizumab (4)  ·  Adrenal Cortex Hormones (3)  ·  Certolizumab Pegol (3)  ·  guselkumab (3)

Sponsors

Takeda (10)  ·  Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (9)  ·  Sixth Affiliated Hospital, Sun Yat-sen University (5)  ·  Alimentiv Inc. (4)  ·  Asan Medical Center (3)  ·  Erasmus Medical Center (3)  ·  Mayo Clinic (3)  ·  Prof. Arie Levine (3)  ·  AbbVie (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2)  ·  Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW (2)  ·  Biogen (2)  ·  Cedars-Sinai Medical Center (2)  ·  Centre Hospitalier Universitaire de Saint Etienne (2)  ·  Children's Hospital of Fudan University (2)

Countries

United States (41)  ·  Canada (21)  ·  France (16)  ·  Netherlands (14)  ·  China (12)  ·  Israel (10)  ·  Belgium (9)  ·  United Kingdom (9)  ·  Italy (7)  ·  Denmark (6)  ·  Spain (6)  ·  Australia (5)  ·  South Korea (5)  ·  Czechia (4)  ·  Germany (4)

Top investigators

Arie Levine, MD (3)  ·  Brian G Feagan, MD (2)  ·  Dan Turner, MD, PhD (2)  ·  David Laharie (2)  ·  Maria O'Sullivan, PhD (2)  ·  Michal Kori, MD (2)  ·  Parakkal Deepak, MBBS, MS (2)  ·  Raanan Shamir, MD (2)  ·  Ron Shaoul, MD (2)  ·  Vipul Jairath, MD (2)

Results publications

PMID 40357993, PMID 10896917, PMID 12432298, PMID 14762782, PMID 1499440, PMID 15058524, PMID 15168373, PMID 16116317, PMID 16279893, PMID 16393226, PMID 16393228, PMID 16500392, PMID 16611269, PMID 1669678, PMID 17058158, PMID 17058159, PMID 17308939, PMID 17593171, PMID 17762967, PMID 18295023, PMID 18564124, PMID 19109962, PMID 1948581, PMID 2179031, PMID 23644079, PMID 23878167, PMID 24284413, PMID 24423431, PMID 24572205, PMID 24953836, PMID 25524543, PMID 25576753, PMID 25705682, PMID 26137304, PMID 26245216, PMID 26275480, PMID 26342731, PMID 2668130, PMID 26765407, PMID 26848182, PMID 27932449, PMID 28090335, PMID 28502609, PMID 29420227, PMID 30649836, PMID 30762274, PMID 30891808, PMID 31194979, PMID 31290715, PMID 31793630

NIH funding

2014 (4), 2016 (3), 2025 (2), 2009 (1), 2015 (1), 2017 (1), 2023 (1), R01DK125495 (1), U01DK134356 (1)